Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a listen-only mode.
Acumen Pharmaceuticals Inc. (ABOS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 9,770,773 | $39,669,338 | 0.89% | |
| 2. | Deep Track Capital David Kroin | 3,952,000 | $16,045,120 | 0.65% | |
| 3. | Laurion Capital Management Benjamin A. Smith | 1,206,548 | $4,898,585 | 0.03% | |
| 4. | Great Point Partners Jeffrey Jay And David Kroin | 1,051,267 | $4,268,144 | -6% | 0.83% |
| 5. | Driehaus Capital Richard Driehaus | 550,349 | $2,234,417 | -3% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 35,000 | Director | 172,324 | 2021-07-06 | Filing | |
| $16.00 | 312,500 | Large Shareholder | 3,352,693 | 2021-07-06 | Filing | |
| $16.00 | 750,000 | Large Shareholder | 3,951,156 | 2021-07-06 | Filing | |
| $16.00 | 6,250 | Director | 6,250 | 2021-07-06 | Filing | |
| $14.88 | 450,000 | Large Shareholder | 3,417,075 | 2021-07-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 3,417,075 | $13,873,325 | 3.42% | |
| 2. | 734,737 | $2,983,032 | 0% | |
| 3. | 671,631 | $2,726,821 | 0% | |
| 4. | 392,060 | $1,591,764 | 0.02% | |
| 5. | 196,539 | $797,948 | 0.01% |
News See All
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript
Operator: Good day. Thank you for standing by. Welcome to the Acumen Pharmaceuticals, Q3 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
5 Best Immunotherapy Stocks To Buy Now
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of Alzheimer’s disease.
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky's RA Capital
In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky's RA Capital.
Billionaire Hedge Funds
